Headlines about Stryker (NYSE:SYK) have been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the medical technology company an impact score of 46.9829233633908 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Stryker (SYK) Cut to Sell at Zacks Investment Research (americanbankingnews.com)
- Stryker Corporation, (NYSE: SYK) – Investor’s Alert (Beta Factor in Focus) – Stock Watch (stocksnewstimes.com)
- Basic Trading Data for Stryker Corporation (SYK) – Market Movers (financialqz.com)
- Notable ETF Outflow Detected – IHI, DHR, SYK, ISRG (nasdaq.com)
- Stryker Corporation (NYSE:SYK) – Stock’s Price to Earnings Ratio (P/E) – Brief Analysis – Nasdaq Journal (press release) (nasdaqjournal.com)
Stryker (NYSE SYK) traded up $1.00 on Friday, hitting $161.28. 1,181,670 shares of the company traded hands, compared to its average volume of 1,090,000. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker has a 1 year low of $119.17 and a 1 year high of $164.20. The firm has a market cap of $60,360.00, a PE ratio of 34.39, a P/E/G ratio of 2.30 and a beta of 0.78.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be paid a $0.47 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, December 28th. Stryker’s payout ratio is currently 40.09%.
Several analysts have commented on SYK shares. SunTrust Banks restated a “buy” rating and set a $161.00 price objective on shares of Stryker in a research note on Monday, October 2nd. Royal Bank of Canada restated a “buy” rating and set a $155.00 price objective on shares of Stryker in a research note on Monday, October 2nd. Cowen set a $160.00 price objective on shares of Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Robert W. Baird restated a “hold” rating and set a $161.00 price objective on shares of Stryker in a research note on Friday, October 27th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Stryker currently has an average rating of “Hold” and a consensus target price of $156.60.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.40% of the company’s stock.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.